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Natural approaches in metabolic syndrome management
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A b s t r a c t
Metabolic syndrome (MetS) is characterized as a group of cardiometabolic 
risk factors that raise the risk for heart disease and other health problems, 
such as diabetes mellitus and stroke. Treatment strategies include phar-
macologic interventions and supplementary (or “alternative”) treatments. 
Nutraceuticals are derived from food sources (isolated nutrients, dietary 
supplements and herbal products) that are purported to provide health 
benefits, in addition to providing basic nutritional value. Nutraceuticals are 
claimed to prevent chronic diseases, improve health, delay the aging pro-
cess, increase life expectancy, and support the structure and function of the 
body. The study of the beneficial effects of nutraceuticals in patients with 
MetS, including product standardization, duration of supplementation and 
definition of optimal dosing, could help better define appropriate treatment. 
This review focuses on widely marketed nutraceuticals (namely polyphenols, 
omega-3 fatty acids, macroelements and vitamins) with clinically demon-
strated effects on more than one component of MetS.
Key words: metabolic syndrome, vitamins, cardiovascular risk, 
macroelements, omega-3 fatty acids, polyphenols, nutraceuticals.
Introduction
Metabolic syndrome (MetS) is defined as the coexistence of risk fac-
tors of metabolic origin (insulin resistance, hyperinsulinemia, impaired 
glucose tolerance, type 2 diabetes mellitus, visceral obesity, atherogenic 
dyslipidaemia and/or, high blood pressure) that elevate risk for cardio-
vascular disease [1–3]. The most important components of MetS are re-
lated to each other: (1) obesity and lack of physical activity contribute to 
the development of insulin resistance, which is associated with increases 
in the concentration of triglycerides and low-density lipoprotein particles 
and decreases in high-density lipoprotein cholesterol (HDL-C), favoring 
the formation of atherosclerotic plaques, leading to coronary heart and 
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cerebrovascular disease [4]; (2) insulin resistance 
contributes to higher levels of serum insulin and 
glucose, precursors to the development of diabe-
tes mellitus [5]; (3) hyperinsulinemia results in 
excessive renal sodium retention and elevations 
in blood pressure [6]; (4) alteration of the intrin-
sic cellular expression of endothelial factors caus-
es an increase in blood pressure associated with 
endothelial dysfunction and impaired generation 
of nitric oxide (NO) [7]. In addition to genetic pre-
disposition, there are important environmental 
factors that can influence the pathogenesis of 
MetS; positive changes in lifestyle can beneficially 
impact all features of MetS [8].
The consumption of large quantities of fruits, 
vegetables, fish and dietary supplements are im-
portant for antioxidant and anti-inflammatory ef-
fects [9]. Currently, there is considerable interest in 
the favorable effect of antioxidants in fruits and 
vegetables on obesity and cardiovascular disease 
[10, 11]; noteworthy are also polyunsaturated fat-
ty acids, which have a positive effect on hyperten-
sion, insulin resistance and triglycerides [12, 13]. 
An adequate intake of foods containing antioxi-
dant compounds with an anti-inflammatory effect 
reduces the incidence of MetS [14] and the factors 
that determine this pathological condition [15–18].
Effects of nutraceuticals on metabolic 
syndrome components
Abdominal obesity
Green tea is a natural source of antioxidants in 
the form of catechins, particularly epigallocatechin 
gallate (EGCG) [19, 20]. Flavonoids of this group in-
hibit the expression of inducible NO synthase that 
potentiates inflammation, platelet aggregation, 
and oxidative stress [19]. Experimentally drinking 
or eating green tea significantly reduces both body 
fat and body weight (BW) [21]. Obese hypertensive 
patients were treated for 3 months with extracts 
of green tea. The study group experienced a de-
crease in anthropometric parameters (BW from 
73.2 to 71.9 kg, p < 0.001; body mass index (BMI) 
from 27.4 to 26.9 kg/m2, p < 0.001, and waist cir-
cumference from 95.8 to 91.5 cm, p < 0.001) [22]. 
The polyunsaturated omega-3 fatty acids are 
important supplements, which include linolenic 
acid (ALA), eicosapentaenoic acid (EPA) and doco-
sahexaenoic acid (DHA). These long chain fatty ac-
ids are not synthesized in the body, so they must 
be derived from exogenous sources such as ma-
rine fish. It is important to maintain a proper ratio 
of omega-6 and omega-3 fatty acids [23]; research 
has shown that ALA has no effect on obesity, while 
EPA and DHA reduce adipose tissue mass [24], es-
pecially when combined with lifestyle modifica-
tion interventions [25].
Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is 
a natural polyphenol that is produced by grapes, pea-
nuts, berries and Polygonum cuspidatum (Japanese 
knotweed) [26, 27]. A systematic review has shown 
that resveratrol does not consistently improve BMI 
or BW (p > 0.05), fat mass, fat volume, or abdominal 
fat distribution (p > 0.05). Instead this polyphenol 
has been shown to have a significant positive effect 
(p < 0.05) on inflammatory markers [28].
Dinca et al. wanted to clarify the role of vita- 
min D supplementation on adipokines through 
a  systematic review and meta-analysis of nine 
randomized placebo-controlled trials (RCTs) [29]. 
These investigators did not find a  significant 
change in plasma concentrations of adiponectin 
and leptin after vitamin D supplementation. In 
meta-regression, changes in plasma leptin con-
centrations and in plasma concentrations of ad-
iponectin following vitamin D supplementation 
were found to be independent of the duration of 
treatment [29]. 
Nimitphong et al. investigated the effects of 
vitamin D supplementation for 3 months on an-
thropometric measurements [30]. Forty-seven 
subjects with impaired fasting glucose (IFG) and/
or impaired glucose tolerance (IGT) were random-
ized into three groups: control (n = 18), vitamin D
2 
(20,000 IU weekly, n = 19) or vitamin D3 (15,000 IU 
weekly, n = 10). After 3 months, waist circum-
ference (WC) had significantly decreased in sub-
jects in the vitamin D supplementation group. BW 
(p = 0.05), systolic blood pressure (SBP, p = 0.05), 
BMI (p = 0.06), and HOMA-IR (p = 0.09) also 
decreased, but not significantly. Subjects with 
an increase of total 25(OH)D levels > 10 ng/ml 
(23 of 29 subjects) had significant reductions in 
HOMA-IR and an increase in disposition index [30].
Di Pierro et al. in a  randomized, controlled 
study evaluated the tolerability and the efficacy 
of curcumin in overweight subjects with meta-
bolic syndrome, with a focus on impaired glucose 
intolerance and android-type fat accumulation 
[31]. Curcumin is the major bioactive ingredient 
extracted from the rhizome of the plant Curcu-
ma longa (turmeric). Forty-four subjects, selected 
among those who after 30 days of diet and in-
tervention lifestyle had a weight loss < 2%, were 
treated for 30 days with either daily treatment 
of a  curcumin-based product or pure phosphati-
dylserine [31]. Curcumin administration increased 
weight loss from 1.88% to 4.91%, enhanced per-
centage reduction of body fat (from 0.70% to 
8.43%), increased waistline reduction (from 2.36% 
to 4.14%), improved hip circumference reduction 
from 0.74% to 2.51%, and enhanced reduction of 
BMI (from 2.10% to 6.43%) (p < 0.01 for all com-
parisons) [31]. The impact of a natural supplement 
(Kepar; Rikrea, Italy), containing several plant ex-
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tracts such as curcuma longa, silymarin, guggul, 
chlorogenic acid, and inulin, was evaluated in 
78 patients with metabolic syndrome (MetS; 
45 men; age: 62 ±9 years) [18]. Kepar at a dose 
of 2 pills/day was given for 4 months as add-on 
therapy to the ongoing treatment, maintained at 
fixed doses for the entire study; after 4 months 
the investigators found significant reductions in 
BW (from 81.1 ±13.5 to 79.4 ±12.5 kg, p < 0.0001), 
BMI (from 29.6 (23.7) to 29.3 (21.9) kg/m2, p = 
0.001), and WC (from 105 ±11 to 102 ±10 cm, 
p = 0.0004), as well as in fasting glucose (from 
6.5 (11.7) to 6.4 (7.6) mmol/l, p = 0.014) and total 
cholesterol (TC) (from 4.8 ±1.4 to 4.5 ±1.0 mmol/l, 
p = 0.03). No significant changes were found in 
the other appraised parameters, including oxida-
tive stress [18].
Blood pressure
Pomegranate has been widely used as a  folk 
medicine in many cultures [32]. The content of 
soluble polyphenols in pomegranate juice (PJ) var-
ies within the limits of 0.2–1.0%, and they include 
tannins, ellagic tannins, anthocyanins, catechins, 
as well as gallic and ellagic acids [33, 34]. The 
consumption of PJ reduces blood pressure, and in 
hypertensive patients affects the activity of angio-
tensin-converting enzyme (ACE) [35]. Aviram et al. 
noted a 36% decrease in serum ACE activity and 
a 5% reduction in systolic blood pressure [36]. The 
PJ has also been shown to beneficially impact oxi-
dative stress [36, 37].
When measured over 8 weeks of treatment, 
green tea also lowers systolic blood pressure (from 
126.2 mm Hg to 118.6 mm Hg; p < 0.05) [21]. 
In another study in obese persons, green tea re-
duced blood pressure (SBP from 145 ±10 mm Hg to 
141 ±8 mm Hg, p = 0.004; DBP from 88 ±4 mm Hg 
to 84 ±3 mm Hg, p < 0.01) and the insulin level 
and improved the lipid profile (p < 0.05) [38].
The pro-health properties of garlic (Allium sa-
tivum) are due to its chemical composition [39, 
40]. High levels of allicin and sulfur reduce blood 
pressure [41]. Data from clinical studies indicate 
that garlic powder is an antihypertensive agent in 
patients with hypertension and reduces both sys-
tolic (aged garlic extract Δ: –2.59 ±1.91 vs. placebo, 
Δ: –1.72 ±1.60) and diastolic (aged garlic extract 
Δ: –1.07 ±1.32 vs. placebo, Δ: –0.31 ±1.17) blood 
pressure [42]. The above results demonstrate that 
garlic as a food supplement may be useful in the 
treatment of MetS [43].
ALA, EPA and DHA also impact systolic and di-
astolic blood pressure in hypertensive patients. It 
has been suggested that the hypotensive proper-
ties of omega-3 fatty acids are associated with an-
giotensin II antagonism and increased production 
of NO [44, 45].
Quercetin, the most abundant dietary flavonol, 
has antioxidant effects in cardiovascular disease. 
Quercetin protects against lipid peroxidation and 
reduces the cytokine-induced cell-surface expres-
sion of vascular cell adhesion molecule-1 (VCAM-1) 
and E-selectin, but the evidence regarding its ef-
fects on blood pressure (BP) has not been con-
clusive [46]. Serban et al. assessed the impact 
of quercetin on BP through a  systematic review 
and meta-analysis of 7 available randomized 
controlled trials; the results of this meta-analy-
sis showed significant reductions in both systolic 
BP (–3.04 mm Hg, p = 0.028) and diastolic BP 
(–2.63 mm Hg, p < 0.001) following supplemen-
tation with this compound [47]. When the stud-
ies were categorized according to quercetin dose, 
there was a significant systolic and diastolic BP-re-
ducing effect in randomized controlled trials with 
doses ≥ 500 mg/day (–4.45 mm Hg, p = 0.007 and 
–2.98 mm Hg, p < 0.001, respectively), and lack of 
a  significant effect for doses < 500 mg/day, but 
indirect comparison tests failed to demonstrate 
significant differences between doses [47].
The International Study of Macro- and Micro- 
Nutrients and Blood Pressure is a cross-section-
al epidemiologic study of 4680 men and wom-
en aged 40 to 59 from 17 population samples 
in Japan, China, the United Kingdom, and the 
United States [48]. The results indicate the po-
tential for increased phosphorus/mineral intake 
to lower blood pressure as part of the recom-
mendations for healthier eating patterns for the 
prevention and control of prehypertension and 
hypertension [48]. Dietary calcium and magne-
sium, correlated with phosphorus intake (partial 
r = 0.71 and r = 0.68), were inversely associated 
with blood pressure; blood pressures were lower 
by 1.9 mm Hg to 4.2 mm Hg systolic/1.2 mm Hg 
to 2.4 mm Hg diastolic for people with intakes 
above versus below country-specific medians for 
all 3 of the minerals [48].
Glycemic and lipid metabolic disorders
Green tea consumption is known to be asso-
ciated with enhanced cardiovascular and met-
abolic health [19, 21]. Supplementation with 
green tea extract results in significant reductions 
in TC (from 5.4 ±1.0 mmol to 5.0 ±0.9 mmol; p = 
0.009), low-density lipoprotein cholesterol (LDL-C) 
(from 3.5 ±1.0 mmol to 3.1 ±0.9 mmol; p = 0.011) 
and triglyceride (TG) (from 1.4 ±0.6 mmol to 1.1 
±0.5 mmol; p = 0.004), and an increase in high- 
density lipoprotein (HDL-C) (from 1.2 ±0.2 mmol 
to 1.4 ±0.3 mmol; p < 0.001) [21].
Rebello et al. examined the effects of a gastro-
intestinal microbiome modulator (GIMM) contain-
ing inulin, β-glucan, blueberry anthocyanins, and 
blueberry polyphenols on metabolic parameters, 
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fecal markers of gut microbiota, and satiety in 
30 overweight or obese individuals aged 18 to 70 
years [49]. After 4 weeks GIMM consumption im-
proved blood glucose tolerance (p = 0.008), and 
the desire to eat was reduced (p = 0.03) com-
pared to the placebo. There were no statistically 
significant differences in insulin sensitivity, fecal 
markers of gut microbiota, or serum lipid concen-
trations between the groups. However, plasma 
ghrelin concentrations significantly decreased in 
the GIMM group (–13.4 ±72.5, p = 0.03) compared 
to the placebo [49]. 
Chokeberry is a  shrub deciduous tree belong-
ing to the Rosaceae family in North America [26]. 
Aronia berries among all known fruits are distin-
guished by the highest antioxidant content. They 
are rich in polyphenols and anthocyanins, includ-
ing flavonols, especially quercetin and kaempferol 
and the cyanidin glycosides. Aronia fruit contains 
organic acids, vitamin C, sugars, pectin, carotene, 
tannin and inorganic compounds including boron, 
fluorine, manganese, molybdenum, iodine and 
iron [27]. Broncel et al. detected beneficial ef-
fects of anthocyanins on metabolic parameters in 
22 healthy volunteers and 25 patients with MetS 
treated with anthocyanins (3 × 100 mg/day) for 
2 months. After 2 months of treatment a signifi-
cant reduction in TC from 242.80 ±34.48 to 227.96 
±33.07 mg/dl (p < 0.001), LDL-C from 158.71 
±35.78 to 146.21 ±34.63 mg/dl (p < 0.01) and tri-
glycerides from 215.92 ±63.61 to 187.58 ±90 mg/dl 
(p < 0.05) was observed, but fasting blood glucose 
levels did not change significantly [50].
White mulberry (Morus alba) is a  plant tradi-
tionally grown in China, Korea, and Japan [51]. 
Mulberry leaf extract lowers postprandial glucose; 
this is due to the fact that it is rich in DNJ (1,5-dide-
oxy-1,5-imino-D-sorbitol), which is an inhibitor of 
α-glucosidase. DNJ inhibits α-glucosidase in the 
small intestine by binding to its active site [51]. An 
open-label, single-group study was conducted in 
10 subjects with initial serum TG level ≥ 200 mg/
dl; subjects ingested capsules containing DNJ-rich 
mulberry leaf extract at 12 mg three times daily 
before meals for 12 weeks [52]. White mulberry 
extract had a  significant impact on the changes 
in the concentration of LDL-C (large LDL-C from 
baseline 18.1 ±5.2 to 20.7 ±4.7 mg/dl at week 12, 
p = 0.047; medium LDL-C from baseline 32.8 ±8.9 
to 43.4 ±9.3 mg/dl at week 12, p < 0.001; small 
LDL-C from baseline 28.7 ±7.1 to 36.2 ±6.9 mg/dl 
at weeks 12; p = 0.005) and HDL-C (mean particle 
size was from baseline 10.40 ±0.18 nm to 10.54 
±0.19 nm at week 12, p = 0.006) subfractions and 
TG (312 ±90 mg/dl at baseline to 252 ±78 mg/dl 
at week 12, p = 0.058) [52]. LDL size is an import-
ant predictor of CV events and progression of CAD 
and evidence suggests that both quality (particu-
larly small, dense LDL) and quantity may increase 
CV risk [16, 53, 54]. A  predominance of small, 
dense LDL particles (LDL-3 to -7) has been recog-
nized as an emerging CV risk factor by the Nation-
al Cholesterol Education Program Adult Treatment 
Panel III [2, 3].
In recent studies Citrus bergamia (known as 
Bergamot) juice was shown to reduce serum lipid 
levels, and this benefit can be attributed to high 
amounts of flavonoids in bergamot juice (neoe-
riocitrin, neohesperidin, naringin) [15]. Toth et al. 
investigated the effects of bergamot extract on 
cardio-metabolic parameters, including plasma 
lipids, atherogenic lipoproteins and subclinical 
atherosclerosis [17]. After 6 months of adminis-
tration bergamot had significantly modified lip-
ids (TC from 6.6 ±0.4 mmol/l to 5.8 ±1.1 mmol/l, 
p < 0.0001; TG from 1.8 ±0.6 mmol/l to 1.5 ±0.9 
mmol/l, p = 0.0020; LDL-C from 4.6 ±0.2 mmol/l 
to 3.7 ±1.0 mmol/l, p < 0.0001; HDL-C increased 
from 1.3 ±0.2 mmol/l to 1.4 ±0.4 mmol/l, p < 
0.0007), LDL-C subfractions (LDL-1 from 41.2 
±0.2% to 49.6 ±0.2%, p < 0.0001; LDL-3, LDL-4 
and LDL-5 particles from 14.5 ±0.1% to 9.0 ±0.1%, 
p < 0.0001; 3.2 ±0.1% to 1.5 ±0.1%, p = 0.0053; 
0.3 ±0.0% to 0.1 ±0.0%, p = 0.0133, respectively) 
and carotid intima-media thickness (cIMT) (from 
1.2 ±0.4 mm to 0.9 ±0.1 mm; p < 0.0001) in pa-
tients with moderate hypercholesterolemia [17].
Ginseng extract obtained from roots, fruits and 
leaves of American ginseng (Panax quinquefolium) 
or Asian ginseng (Panax ginseng) has been widely 
studied for the treatment of diabetes, dyslipidae-
mia, and obesity. It contains many bioactive com-
pounds, ginsenosides (such as Rb1, Rb2, Rc, Rd, 
Re and Rg1; this classification depends on their 
Rf values (from small to large) in thin-layer chro-
matography [55]), which contribute to the regu-
lation of glucose levels and blood pressure [56]. 
One report showed that administration of ginseng 
elevated mood, improved psychophysical and 
physical performance, and reduced fasting blood 
glucose (FBG), hemoglobin A1c (HbA1c) and body 
weight in diabetic patients [57]. In addition to glu-
cose metabolism, ginseng has also been shown to 
regulate lipid metabolism. In one study, ginseng 
was administered through a  diet supplement; 
ginseng treatment lowered serum TC (67–83% of 
control, p < 0.01) and LDL-C (53–81% of control, 
p < 0.01). The decrease in TC and LDL-C was re-
lated to the suppression of β-hydroxy-β-methyl-
glutaryl-CoA (HMG-CoA) reductase and in parallel 
of cholesterol 7α-hydroxylase activity [58]. Cho-
lesterol 7α-hydroxylase (Cyp7a1) catalyzes the 
rate-limiting step in the intrahepatic conversion 
of cholesterol to bile acids. When 7α-hydroxylase 
activity is suppressed, decreased bile acid biosyn-
thesis leads to an increased hepatic cholesteryl 
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ester content, increased hepatic expression of 
ABCA1, and an increased hepatic cholesterol ef-
flux to HDL, resulting in increased plasma HDL-C 
levels [59]. Some clinical studies have suggested 
that ginseng increases the secretion of insulin 
[56]. This stimulation of insulin secretion may be 
due to the following factors: (1) biosynthesis of 
insulin is increased significantly in pancreatic is-
lets by ginseng extract DPG-3-2 (a component of 
ginseng radix) in vivo and in vitro [60]; (2) release 
of insulin is increased by the ginsenoside Rh2. 
This mechanism is related to the release of ace-
tylcholine from nerve terminals in pancreases and 
stimulation of muscarinic M(3) receptors in β-cells 
[61, 62]; and (3) ginseng may prevent β-cell apop-
tosis [63]. Various ginsenosides have been shown 
to upregulate insulin and non-insulin stimulated 
glucose transport in different animal models and 
cell lines. Direct clinical investigations of insulin 
sensitivity using the euglycemic-hyperinsulinemic 
clamp are needed to confirm this mechanism [64]. 
Green tea extract increases the levels of glutathi-
one in the blood and plasma total antioxidant ca-
pacity in patients with MetS [58].
To date it is not clear how the omega-3 fatty ac-
ids reduce the risk of cardiovascular disease. They 
do improve the lipid profile with a decrease in TC, 
LDL-C, and TG and an increase in HDL-C [65]. The 
efficacy of icosapent ethyl (IPE; Vascepa [former-
ly AMR101]; Amarin Pharma Inc., Bedminster, NJ, 
USA) in improving lipid parameters was demon-
strated in a  12-week randomized, placebo-con-
trolled trial (ANCHOR) that enrolled statin-treated 
patients at high cardiovascular risk with well-con-
trolled LDL-C levels and persistently high TG levels 
(at or above 200 mg/dl and less than 500 mg/dl) 
[66]. Compared with placebo, IPE 4 g/day and 
2 g/day reduced median TG levels from baseline 
by 21.5% (p < 0.0001) and 10.1% (p = 0.0005), 
respectively, without increasing LDL-C levels. The 
4 g/day dose decreased LDL-C levels by 6.2% 
(p = 0.007) and significantly reduced other lipid 
parameters, compared with a  light liquid par-
affin placebo, including apolipoprotein B (9.3%; 
p < 0.0001), very-low-density lipoprotein choles-
terol (24.4%; p < 0.0001), lipoprotein-associat-
ed phospholipase A2 (19.0%; p < 0.0001), and 
high-sensitivity C-reactive protein (hs-CRP) (22.0%; 
p = 0.0005) [66]. In 1999 and 2007, two major out-
come trials of cardiovascular disease documented 
the efficacy of omega-3 fatty acids in the prima-
ry and secondary prevention of coronary heart 
disease (CHD). The Italian Group for the Study of 
the Survival of Myocardial Infarction (GISSI)-Pre-
vention study was a  secondary outcomes study 
in which 11,324 post-myocardial infarction (MI) 
patients were randomly assigned to receive a fish 
oil supplement (0.85 g of eicosapentaenoic acid 
(EPA) plus docosahexaenoic acid (DHA)), 0.3 g of 
vitamin E, both, or none [67]. Patients taking ome-
ga-3 fatty acids, but not vitamin E, had a 15% re-
duction (p = 0.02) in the primary endpoint (death, 
nonfatal MI, and stroke), including 20% and 30% 
decreases in total and cardiovascular mortality, 
respectively [67]. In the Japan Eicosapentaenoic 
Acid (EPA) Lipid Intervention Study (JELIS), 18,645 
patients with hypercholesterolemia (80% in pri-
mary and 20% in secondary prevention) received 
statins alone or in combination with highly puri-
fied EPA (1.8 g/day) [68]. Although this study was 
limited to Japanese patients, most of whom were 
postmenopausal women, after 5 years patients 
receiving the combined treatment experienced 
a 19% relative reduction in major coronary events 
(p = 0.01) [68]. Beneficial effects were noted in both 
primary and secondary prevention subgroups, but 
these were significant only in the secondary pre-
vention subgroup (8.7% in the EPA group vs. 10.7% 
in the control group; p = 0.048). In patients with TG 
> 200 mg/dl (> 2.3 mmol/l) and HDL-C < 40 mg/dl 
(< 1.0 mmol/l), risk reduction was 53% compared 
with statin monotherapy [68]. The Reduction of 
Cardiovascular Events with EPA – Intervention Trial 
(REDUCE-IT; NCT01492361) [69] and the STatin Re-
sidual risk reduction with EpaNova in hiGh cardio-
vascular risk paTients with Hypertriglyceridemia 
(STRENGTH; NCT02104817) trial [70] are currently 
under way. These studies should provide valuable 
information on the utility of omega-3 fatty acids 
in combination with statin therapy in high-risk pa-
tients with TG levels of 200–500 mg/dl [71].
Considerable controversy exists regarding 
the association of omega-3 polyunsaturated fat-
ty acids (PUFAs) and major cardiovascular end 
points. Some primary and secondary prevention 
trials suggest that there is no benefit to omega-3 
PUFA supplementation in the prevention of CVD 
[72]. Fourteen randomized controlled trials (RCTs) 
(20,485 subjects enrolled, mean age of partici-
pants was 63.4 years and 79% were male) were 
included in a  meta-analysis. Included patient 
groups were those with stable coronary heart 
disease, recent myocardial infarction, implanted 
cardioverter defibrillators, congestive heart fail-
ure and other cardiovascular diseases. Daily dos-
es of eicosapentaenoic acid or docosahexaenoic 
acid ranged from 0.4 g to 4.8 g. Follow-up ranged 
from 1 to 5 years. Placebo groups received veg-
etable oils, mixed fatty oil and other “inert” or 
poorly defined substances [73]. Omega-3 fatty 
acid supplementation did not reduce the risk of 
overall cardiovascular events (RR = 0.99, 95% CI: 
0.89–1.09; 14 RCTs), risk of all-cause mortality 
(13 RCTs), sudden cardiac death (5 RCTs), myo-
cardial infarction (11 RCTs), fatal myocardial in-
farction (5 RCTs), nonfatal myocardial infarction 
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(7 RCTs), angina and unstable angina (7 RCTs), 
congestive heart failure (6 RCTs) or transient 
ischaemic attack and stroke (seven RCTs) [73]. 
There was a significant reduction in cardiovascu-
lar death (RR = 0.91, 95% CI: 0.84–0.99; 11 RCTs), 
which became non-significant when a study with 
a significant baseline imbalance (for history of an-
gina) was removed. No significant preventive ef-
fect was observed in any of the subgroup analyses 
[73]. Another meta-analysis included 20 random-
ized controlled trials (68,680 participants, average 
age 68 years) that compared omega-3 polyunsat-
urated fatty acid supplementation against other 
diet or placebo for the prevention of primary or 
secondary cardiovascular disease in adults [74]. 
There were no statistically significant associa-
tions between omega-3 PUFA supplementation 
and all-cause mortality (RR = 0.96, 95% CI: 0.91–
1.02; 17 RCTs), cardiac death (RR = 0.91, 95% CI: 
0.85–0.98; 13 RCTs), sudden death (RR = 0.87, 
95% CI: 0.75–1.01; 7 RCTs), myocardial infarction 
(RR = 0.89, 95% CI: 0.76–1.04; 13 RCTs) or stroke 
(RR = 1.05, 95% CI: 0.93–1.18; 9 RCTs). Results for 
absolute risk reductions were not statistically sig-
nificant. Subgroup analyses did not alter the main 
findings. Omega-3 PUFA supplementation was not 
associated with a lower risk of all-cause mortality, 
cardiac death, sudden death, myocardial infarc-
tion or stroke [74].
Vitamin E, a  predominant antioxidant pres-
ent in the LDL particle, blocks the chain reaction 
of lipid peroxidation by scavenging intermediate 
peroxyl radicals [75]. The data on the reduction of 
cardiovascular risk using vitamin E are conflicting, 
with most studies showing no benefit except in 
very specific subpopulations. According to a two-
by-two factorial design, 2545 women and 6996 
men 55 years of age or older, who were at high 
risk for cardiovascular events because they had 
cardiovascular disease or diabetes in addition to 
one other risk factor, received either 400 IU of 
vitamin E daily from natural sources or matching 
placebo and either an angiotensin-converting-en-
zyme inhibitor (ramipril) or matching placebo 
for a  mean of 4.5 years [76]. The primary out-
come was a  composite of myocardial infarction, 
stroke, and death from cardiovascular causes. 
The secondary outcomes included unstable an-
gina, congestive heart failure, revascularization 
or amputation, death from any cause, complica-
tions of diabetes, and cancer [76]. Seven hundred 
and seventy-two patients assigned to vitamin E 
(16.2%) and 739 to placebo (15.5%) had a prima-
ry outcome event (RR = 1.05, 95% CI: 0.95–1.16; 
p = 0.33). There were no significant differences in 
the numbers of deaths from cardiovascular caus-
es (342 of those assigned to vitamin E vs. 328 
of those assigned to placebo; RR = 1.05, 95% CI: 
0.90–1.22), myocardial infarction (532 vs. 524; 
RR = 1.02, 95% CI: 0.90–1.15), or stroke (209 vs. 
180; RR = 1.17; 95% CI: 0.95–1.42). There were 
also no significant differences in the incidence of 
secondary cardiovascular outcomes or in death 
from any cause. There were no significant adverse 
effects of vitamin E [76]. Similarly, The Physicians’ 
Health Study II was a  randomized, double-blind, 
placebo-controlled factorial trial of vitamin E and 
vitamin C that began in 1997 and continued un-
til its scheduled completion in 2007 [77]. There 
were 14,641 US male physicians enrolled, who 
were initially aged 50 years or older, including 
754 (5.1%) men with prevalent cardiovascular dis-
ease at randomization. Each individual received 
supplements of 400 IU of vitamin E every other 
day and 500 mg of vitamin C daily. The composite 
end point was comprised of nonfatal myocardi-
al infarction, nonfatal stroke, and cardiovascular 
disease death [77]. During a  mean follow-up of 
8 years, there were 1245 confirmed major cardio-
vascular events; compared with placebo, vitamin E 
had no effect on the incidence of major cardio-
vascular events (both active and placebo vitamin E 
groups, 10.9 events per 1000 person-years; haz-
ard ratio (HR) = 1.01, 95% CI: 0.90–1.13, p = 
0.86), as well as total myocardial infarction 
(HR = 0.90, 95% CI: 0.75–1.07, p = 0.22), total 
stroke (HR = 1.07, 95% CI: 0.89–1.29, p = 0.45), 
and cardiovascular mortality (HR = 1.07, 95% CI: 
0.90–1.28, p = 0.43); but vitamin E was associat-
ed with an increased risk of hemorrhagic stroke 
(HR = 1.74, 95% CI: 1.04–2.91, p = 0.04) [77].
High-dose niacin (vitamin B3) is used in the 
treatment of hyperlipidemia [78]. Randomized, 
double-blind, placebo-controlled investigations 
showed that sustained-released niacin decreas-
es LDL-C, TC, and TG and raises HDL-C [79–81]. 
A  multicenter, randomized, double-blind clinical 
trial enrolled 122 patients with confirmed di-
agnosis of primary dyslipidemia (LDL cholester-
ol > 4.14 mmol/l (160 mg/dl) and triglycerides 
< 9 mmol/l (800 mg/dl)) into 3 treatment groups: 
(1) Niaspan 1,000 mg/day; (2) Niaspan 2,000 mg/
day; and (3) placebo. The primary treatment end-
point was LDL-C level. This endpoint was not sig-
nificantly affected by placebo (0.2% increase), but 
Niaspan decreased LDL-C by 5.8% (1,000 mg/day) 
and 14.6% (2,000 mg/day) (p < 0.001) [79]. Like-
wise, with placebo there were significant changes 
in TC, triglycerides, lipoprotein(a), and apoprotein B, 
whereas both Niaspan 1,000 and 2,000 mg/day 
significantly (p < 0.001) decreased these param-
eters. In addition, both Niaspan groups showed 
significant (p < 0.001) increases in HDL-C (17% 
and 23%, respectively), including HDL subfrac-
tions. This trial demonstrated a cholesterol-mod-
ifying effect of Niaspan consistent with those 
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reported for niacin, but demonstrated a  better 
tolerance for flushing [79]. Another multicenter 
trial evaluated the safety and efficacy of esca-
lating doses of Niaspan (from a dose of 375 mg/
day to 500–3,000 mg/day in 25 weeks) and pla-
cebo in 131 patients with primary hyperlipidemia 
on the percent change from baseline in levels of 
LDL-C and apolipoprotein B. Significant decreas-
es from baseline in levels of LDL-C and apolipo-
protein B became apparent with the 500-mg/day 
dose and were consistent at all subsequent doses 
(p ≤ 0.05), reaching 21% and 20%, respectively, at 
the 3,000-mg/day dose [81]. Significant increases 
from baseline in levels of HDL-C became appar-
ent with the 500-mg/day dose and were consis-
tent at all subsequent doses (p ≤ 0.05), reaching 
30% at the 3,000-mg dose. Significant decreases 
from baseline in triglycerides and lipoprotein(a) 
occurred at the 1,000-mg dose and were apparent 
at all subsequent doses (p ≤ 0.05), reaching 44% 
and 26%, respectively, at the 3,000-mg dose [81]. 
Previously available randomized clinical trial data 
assessing the clinical efficacy of niacin have been 
challenged by results from AIM-HIGH and HPS-2 
THRIVE, which failed to demonstrate a reduction 
in CVD event incidence in patients with estab-
lished CVD treated with niacin as an adjunct to 
intensive simvastatin therapy [82, 83].
Equol is produced by intestinal bacteria from 
isoflavone daidzein. Liu et al. in a randomized con-
trolled trial examined the effect of whole soy (soy 
flour) and purified daidzein on cardiovascular bio-
markers in prehypertensive postmenopausal wom-
en who were equol producers [84]. Two hundred 
seventy eligible women were randomized to either 
one of the three treatments: 40 g soy flour (whole 
soy group), 40 g low-fat milk powder + 63 mg daid-
zein (daidzein group), or 40 g low-fat milk powder 
(placebo group) daily each for 6 months; after 
6 months of treatment, serum LDL-C decreased 
by 7.95% (whole soy group) and 6.32% (daidzein 
group) compared to the placebo group [84].
Several studies have focused on the effects 
of calcium intake on serum lipid concentrations 
in postmenopausal women with dyslipidemia. In 
one trial, a total of 190 premenopausal women and 
182 postmenopausal women with dyslipidemia 
were given 800 mg calcium/day or a  placebo for 
2 years in a double-blind, randomized, placebo-con-
trolled trial [85]. The change in TC in premeno-
pausal women and postmenopausal women after 
calcium supplementation was 0.04 ±0.07 mmol/l 
compared with 0.61 ±0.21 mmol/l, respectively, 
and there was a significant interaction effect be-
tween calcium supplementation and menopaus-
al status on serum cholesterol concentrations 
(from baseline 5.56 ±0.65 mmol/l to 2 years 5.87 
±0.71 mmol/l; p < 0.001) [85]. In the prospective 
Data from an Epidemiologic Study on the Insulin 
Resistance Syndrome study (DESIR) with 9 years 
of follow-up, in a  large cohort drawn from the 
French general population, the consumption of 
dairy products and cheeses, as well as the density 
of calcium (defined as the amount of calcium in-
gested per 1,000 kcal) in the diet, were associat-
ed with a lower incidence of MetS and were also 
associated with a lower incidence of IFG or type 2 
diabetes [86]. Although dairy products contain 
saturated fatty acids they can reduce the risk of 
cardiovascular disease. The objective of one study 
was to determine the early (7 days) and sustained 
(4 and 12 weeks) effects of adequate-dairy (AD) 
compared with low-dairy (LD) diets in subjects 
with metabolic syndrome [87]. Forty overweight 
and obese adults with metabolic syndrome were 
randomly assigned to receive AD (3.5 daily serv-
ings) or LD (< 0.5 daily servings) weight-main-
tenance diets for 12 weeks. The AD decreased 
malondialdehyde and oxidized LDL at 7 days (35% 
and 11%, respectively; p < 0.01), with further de-
creases by 12 weeks [87]. Inflammatory markers 
were suppressed with intake of AD, with decreas-
es in tumor necrosis factor-α (TNF-α) at 7 days 
and further reductions through 12 weeks (35%; 
p < 0.05); decreases in interleukin-6 (IL-6) (21%; 
p < 0.02) and monocyte chemoattractant protein 1 
(14% decrease at 4 weeks, 24% decrease at 
12 weeks; p < 0.05); and a corresponding 55% in-
crease in adiponectin at 12 weeks (p < 0.01). The 
LD exerted no effect on oxidative or inflammatory 
markers. Diet had no effect on body weight; how-
ever, AD significantly reduced waist circumference 
and trunk fat (p < 0.01 for both), while LD exerted 
no effect [87]. An higher intake of dairy products 
rich in calcium inhibits the generation of reactive 
oxygen species, thus relieving oxidative stress, 
and may help reduce the risk of developing MetS. 
Adipose tissue reactive oxygen species (ROS) pro-
duction and NADPH oxidase and plasma malondi-
aldehyde (MDA) were reduced by the high-Ca diet 
(p < 0.001) compared with the basal diet, and ROS 
and MDA were further decreased by the high-dairy 
diet (p < 0.001) [88]. The high-Ca and -dairy di-
ets also resulted in suppression of adipose tissue 
TNF-α and IL-6 (p = 0.001) compared with the bas-
al diet, whereas an inverse pattern was noted for 
adiponectin and IL-15 (p = 0.002). Consequently, 
a  high-dairy eucaloric diet resulted a  reduction 
of 29% (p < 0.01) in C-reactive protein. Adiponec-
tin decreased by 8% in subjects fed the eucaloric 
high-dairy diet (p = 0.003) and 18% in those fed 
the hypocaloric high-dairy diet (p < 0.05) [88].
Rosenblat et al. evaluated the effects of PJ 
(50 ml per day for 3 months) given to ten diabetic 
patients and ten placebo patients on glycemic pa-
rameters and oxidative stress in their serum and 
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macrophages [89]. The PJ consumption did not 
affect serum glucose, cholesterol or triglyceride 
levels, but it resulted in a significant reduction in 
serum lipid peroxides by 56%, in cellular perox-
ides by 71%, and in oxidized LDL (Ox-LDL) by 37%. 
The PJ consumption by diabetic patients did not 
worsen diabetic parameters, but rather resulted in 
anti-oxidative effects on serum and macrophages, 
which could impact atherogenesis in these pa-
tients [89].
It has been shown that zinc deficiency in-
creases the risk of glucose intolerance, diabetes, 
insulin resistance, atherosclerosis, and CHD [90]. 
In diabetic patients given 12 weeks of therapy 
with zinc at a  concentration of 100 mg/day, TC 
and triglyceride levels decreased and HDL-C levels 
increased. These results will require validation in 
a larger placebo-controlled trial [90].
Effects of nutraceuticals on vascular damage
Prothrombotic and proinflammatory states
Guerrero-Romero et al. examined the relation-
ship between MetS, hypomagnesemia, inflamma-
tion, and oxidative stress in patients with MetS 
(84 women and 63 men) compared with healthy 
control subjects [91]. Multivariate analysis showed 
a strong association between MetS and hypomag-
nesemia (OR = 1.9; 95% CI: 1.3–7.1), inflammation 
(OR = 1.7; 95% CI: 1.4–8.4), and oxidative stress 
(OR = 1.4; 95% CI: 0.9–12.6). The interaction of 
inflammation and oxidative stress is related to 
and increases the risk for MetS, whereas serum 
magnesium levels and MetS are independently 
associated [91].
Some studies suggest that omega-3 polyun-
saturated fatty acids reduce the damage caused 
by oxidative stress and restore free radical ho-
meostasis [92, 93]. Free radicals adversely alter 
lipids, proteins, and DNA and trigger a  number 
of human diseases. A balance between free rad-
icals and antioxidants is necessary for proper 
physiological function. If free radicals overwhelm 
the body’s ability to regulate them, a  condition 
known as oxidative stress ensues [92]. The hu-
man body has several mechanisms to counteract 
oxidative stress by producing antioxidants, which 
are either naturally produced in situ, or externally 
supplied through foods and/or supplements [91]. 
The mechanism of action is not completely under-
stood, but the effect of omega-3 supplementation 
involves an increase in glutathione (GSH) plasma 
levels and in the concentration of antioxidant en-
zymes (glutathione peroxidase and copper/zinc 
superoxide dismutase) and a reduction in the con-
centration of malonic dialdehyde [94, 95].
Vitamin C is a  scavenger antioxidant and de-
creases peroxyl radical formation [96]. In addition 
to blocking lipid peroxidation by trapping peroxyl 
radicals in the aqueous phase, vitamin C helps to 
regenerate α-tocopherol from α-tocopherol radi-
cals in membranes and lipoproteins, and also rais-
es intracellular glutathione levels, thus playing an 
important role in protein thiol group protection 
against oxidation [97], and helps normalize endo-
thelial vasodilator function in patients with heart 
failure by increasing the availability of NO [98]. 
High doses of vitamin C have also been associated 
with decreased levels of NO production by endo-
thelial cells. The overloading of ascorbic acid (AA) 
in cells can change the oxidative-reduction status 
inside cells. This could decrease the availability of 
NO, through the formation of peroxynitrite. NO 
can move very rapidly through membranes, and 
hence the reactions of inactivation may also occur 
in the extracellular space between cells. Suppres-
sion of NO generation appears to be one of the 
mechanisms by which AA mediates angiostat-
ic effects [99]. A  study reported that vitamin C 
slowed the progression of atherosclerosis in 
men and women older than 55 years [100]. Brit-
ish researchers found that higher blood levels of 
vitamin C were directly and inversely related to 
death from all causes and specifically death from 
ischemic heart disease in both men and women 
[101]. The researchers strongly advocated modest 
consumption of fruits and vegetables, since their 
results suggested that the equivalent of one extra 
serving of vitamin C rich food reduced the risk of 
death by 20% [102]. Vitamin C at daily dosages 
of 500 mg has been shown to increase red cell 
glutathione by 50% [103]. Glutathione is not only 
a major antioxidant responsible for inhibiting lipid 
peroxidation, but is also a key agent responsible 
for stabilizing immune function [96].
Observational data suggest a  link between 
menaquinone (MK, vitamin K
2) intake and car-
diovascular (CV) health. MK intervention trials 
with vascular endpoints are lacking. Knapen et al. 
investigated long-term effects of MK-7 (180 µg 
MenaQ7/day) supplementation on arterial stiff-
ness in a  double-blind, placebo-controlled trial 
in healthy postmenopausal women (n = 244) 
who received either placebo (n = 124) or MK-7 
(n = 120) for 3 years [104]. Circulating desphos-
pho-uncarboxylated matrix Gla-protein (dp-uc-
MGP) as well as acute phase markers IL-6, hs-CRP, 
TNF-α and markers for endothelial dysfunction 
(vascular cell adhesion molecule-1 (VCAM-1) and 
E-selectin), and advanced glycation end products 
(AGEs) were measured [105]. At baseline dp-uc-
MGP was associated with cIMT, diameter, carot-
id-femoral and carotid-radial pulse wave velocity 
(cfPWV), and with the mean z-scores of acute 
phase markers (APM score) and of markers for 
endothelial dysfunction (EDF score); after 3 years 
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of MK-7 supplementation, cfPWV and the stiff-
ness index β significantly decreased in the total 
group, whereas distension, compliance, distensi-
bility, Young’s modulus, and the local carotid PWV 
(cPWV) improved in women having a  baseline 
stiffness index β above the median of 10.8. MK-7 
reduced dp-ucMGP by 50 % compared to placebo, 
but did not influence the markers for acute phase 
and endothelial dysfunction [105].
Matrix metalloproteinases (MMPs) are import-
ant in atherogenesis [106]. Endothelial dysfunc-
tion represents an alteration of normal endothelial 
function, which involves the loss of some struc-
tural features and/or function. The endothelium 
can be considered a true autocrine and paracrine 
organ, capable of secreting, in response to a large 
variety of signals, a number of chemical mediators 
[106]. The relationship between MMPs and tradi-
tional risk factors for cardiovascular disease (CVD) 
and any influence of lifestyle changes are large-
ly unknown. Furenes et al. studied the effects of 
3 years of dietary counseling and/or n-3 PUFA sup-
plementation (2.4 g/day) on the levels of MMP-9, 
tissue inhibitor of metalloproteinase (TIMP-1) and 
pregnancy-associated plasma protein (PAPP-A) in 
a population of elderly male smokers at high risk 
of CVD (n = 563, age 70 ±6 years) and subjects 
with previous acute myocardial infarction (AMI) 
[107]. Smokers had significantly higher levels 
of MMP-9 (p < 0.0001), and TIMP-1 levels were 
lower in subjects with previous AMI (p = 0.021). 
MMP-9 was significantly correlated with LDL-C 
and inversely with HDL-C (both p < 0.0001). Signif-
icant reductions in MMP-9 and PAPP-A levels after 
36 months were found in all study groups, but 
without between-group differences [107]. They 
further explored the association between these 
markers and different disease entities, cIMT and 
traditional risk factors for CVD. Smokers had sig-
nificantly higher levels of MMP-9 (p < 0.0001), and 
TIMP-1 levels were lower in subjects with previ-
ous AMI (p = 0.021). MMP-9 was significantly cor-
related with LDL-C and inversely with HDL-C (both 
p < 0.0001). Significant reductions in MMP-9 and 
PAPP-A  levels after 36 months were found in all 
study groups, but without between-group differ-
ences [107].
Black rice and its pigment fraction have shown 
anti-atherogenic activities in several animal mod-
els, but whether there are beneficial effects in 
humans remains unknown. Wang et al. investi-
gated the influence of black rice pigment fraction 
(BRF) supplementation on selected cardiovascular 
risk factors in patients with CHD [108]. Sixty pa-
tients with CHD aged 45–75 years were random-
ly divided into two groups. In the test group, the 
diet was supplemented with 10 g of BRF derived 
from black rice for 6 months, while in the place-
bo group, the diet was supplemented with 10 g 
of white rice pigment fraction (WRF) derived from 
white rice [108]. At baseline, plasma antioxidant 
status and the levels of inflammatory biomark-
ers and other measured variables were similar 
between the two groups. After 6 months’ inter-
vention, compared to WRF supplementation, BRF 
supplementation greatly enhanced plasma total 
antioxidant capacity (TAC) (BRF group from base-
line 11.1 ±3.53 to 6 months 12.4 ±4.24, change 
1.29 ±2.96; WRF group from baseline 10.3 ±2.73 
to 6 months 9.70 ±2.30, change –0.61 ±1.69; 
p = 0.003), significantly reduced plasma lev-
els of soluble vascular cell adhesion molecule-1 
(sVCAM-1) (BRF group from baseline 1367 ±756 
to 6 months 993 ±532, change –373 ±492; WRF 
group from baseline 1236 ±548 to 6 months 
1208 ±690, change –28.2 ±691; p = 0.03), soluble 
CD40 ligand (sCD40L) (BRF group from baseline 
8.36±4.09 to 6 months 5.73 ±2.37, change –2.63 
±3.27; WRF group from baseline 8.25 ±4.53 to 
6 months 8.85 ±4.73, change 0.60 ±4.43; 
p = 0.002) and hs-CRP (BRF group from baseline 
3.82 ±1.82 to 6 months 2.55 ±1.66, change –1.27 
±1.66; WRF group from baseline 3.58 ±1.71 to 
6 months 3.82 ±1.96, change 0.24 ±1.99; p = 
0.002) in the test group. No significant changes 
were observed in plasma total superoxide dis-
mutase (T-SOD) activity, lipid levels or cIMT be-
tween the two groups [108].
Carotid intima-media thickness and other 
non-invasive vascular parameters
Increased cIMT predicts risk for CV events [109]. 
In fact, increased cIMT is considered a manifesta-
tion of subclinical atherosclerosis, and it was in-
cluded in the list of conditions of organ damage in 
the European guidelines of arterial hypertension 
[110] and in the European guidelines for Cardio-
vascular Prevention and Rehabilitation [111]. The 
ease of performing the measurement and the re-
producibility of the method make cIMT an attrac-
tive biomarker, potentially useful as a therapeutic 
target in patients at increased CV risk [100].
Aviram et al. studied the effects of PJ in pa-
tients with carotid atherosclerosis (CAS), high 
blood pressure and changes in oxidative stress 
[112]. Their results suggest that consumption of 
PJ reduces cIMT by up to 30% and systolic blood 
pressure by 12% and these effects may be related 
to the powerful antioxidant properties of polyphe-
nols [112].
Ethyl alcohol in small quantities, without taking 
into account type of beverage, may provide pro-
tection against cardiovascular or cerebrovascular 
disease [113]. Red wine has antioxidant activity 
through an effect of polyphenol flavonoids [113]. 
Resveratrol, as an isolated substance, is now being 
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studied as a  potential drug for cardioprotection 
[114]. In a small survey conducted in the Nether-
lands, the use of dietary bioflavonoids, phenolic 
acids and quercetin showed a reduced incidence 
of myocardial infarction and sudden death [115].
Quercetin-rich black tea, apples and onions 
were the best foods evaluated, because they 
contain polyphenols in amounts similar to those 
found in red grapes used for wine production and 
grape juice, and consumption of black tea in the 
short and long term has been shown to reverse 
endothelial vasomotor dysfunction in patients 
with CAD [116].
Vegetarian diets have been associated with 
atherosclerosis protection, with healthier athero-
sclerosis risk profiles, as well as lower prevalence 
of, and mortality from, ischemic heart disease 
and stroke [105]. Vitamin B12 deficiency is high-
ly prevalent in vegetarians; this can be partially 
alleviated by taking dairy/egg products in lacto- 
ovo-vegetarians. Vascular studies have demon-
strated impaired arterial endothelial function and 
increased cIMT as atherosclerosis surrogates in 
such metabolic vitamin B12 deficient populations 
[117]. Regular monitoring of vitamin B12 status is 
thus potentially beneficial for early detection and 
treatment of metabolic vitamin B12 deficiency in 
vegans, and possibly for prevention of atheroscle-
rosis-related diseases [117].
The B-PROOF study is a double-blind, random-
ized controlled trial, including 2919 elderly aged 
at least 65 years, with hyperhomocysteinemia 
(12–50 µmol/l), treated with B-vitamins (500 µg 
vitamin B12 and 400 µg folic acid) or placebo for 
2 years [118]. In a subgroup (n =  569), the effect of 
B-vitamins on pulse wave velocity (PWV) was in-
vestigated as a measurement of arterial stiffness; 
to measure atherosclerosis, cIMT measures were 
used. Compared to placebo, B-vitamin supplemen-
tation lowered serum homocysteine by 3.6  µmol/l 
(p  < 0.001) [118]. Analysis of covariance showed 
no effect of supplementation on PWV levels, and 
this was not different for patients without in-
creased arterial stiffness at baseline. Furthermore, 
no effect on cIMT was observed [119]. In the 
Study of the Effectiveness of Additional Reduc-
tions in Cholesterol and Homocysteine (SEARCH) 
trial, a  double-blind randomized trial (intention 
to treat), 12,064 subjects with a history of myo-
cardial infarction were either currently on or had 
a clear indication for statin therapy, and had a TC 
concentration of at least 3–5 mmol/l [120]. Among 
patients given 2 mg of folic acid and 1 mg of vi-
tamin B12 daily versus placebo, there was no dis-
cernible cardiovascular benefit to vitamin therapy. 
Vegetarians are more vascular-healthy, but those 
with a  subnormal vitamin B12 status have im-
paired arterial endothelial function and increased 
intima-media thickness. In a double-blind, place-
bo-controlled, randomized crossover study [121], 
50 healthy vegetarians (vegetarian diet for at least 
6 years) were recruited. Vitamin B12 (500 µg/day) 
or identical placebo was given for 12 weeks with 
10 weeks of placebo washout before crossover 
(n = 43), and then open label vitamin B12 for an ad-
ditional 24 weeks (n = 41). Vitamin B12 supplemen-
tation significantly increased serum vitamin B12 
levels (p < 0.0001) and lowered plasma homocys-
teine (p < 0.05) [121]. After vitamin B12 supple-
mentation but not placebo, significant improve-
ment of flow-mediated dilation of the brachial 
artery (FMD) (6.3 ±1.8% to 6.9 ±1.9%; p < 0.0001) 
and of cIMT (0.69 ±0.09 mm to 0.67 ±0.09 mm, 
p < 0.05) were observed, with further improve-
ment in FMD (to 7.4 ±1.7%; p < 0.0001) and IMT 
(to 0.65 ±0.09 mm; p < 0.001) after 24 weeks of 
open label vitamin B12 [121]. There were no sig-
nificant changes in blood pressures or lipid pro-
files. On multivariate analysis, changes in B12 
(β = 0.25; p = 0.02) but not homocysteine were re-
lated to changes in FMD (R = 0.32; F value = 3.19; 
p = 0.028) [121].
Hodis et al. determined whether reduction 
of plasma total homocysteine (tHcy) levels with 
B vitamin supplementation reduces subclini-
cal atherosclerosis progression [122]. This dou-
ble-blind clinical trial recruited 506 participants 
40 to 89 years of age with an initial tHcy 
> 8.5 µmol/l without diabetes and cardiovascu-
lar disease; patients were randomized to high-
dose vitamin B supplementation (5 mg folic acid  
+ 0.4 mg vitamin B12 + 50 mg vitamin B6) or match-
ing placebo for 3.1 years [122]. Although the over-
all cIMT progression rate was lower with vitamin B 
supplementation than with placebo, statistically 
significant between-group differences were not 
found (p = 0.31) [122]. However, among subjects 
with baseline tHcy ≥ 9.1 µmol/l, those randomized 
to vitamin B supplementation had a  statistically 
significantly lower average rate of cIMT progres-
sion compared with placebo (p = 0.02); among 
subjects with a baseline tHcy < 9.1 µmol/l, there 
was no significant treatment effect (p = 0.02) [99]. 
Vitamin B supplementation had no effect on pro-
gression of aortic or coronary artery calcification 
overall or within subgroups [122].
Vitamin D receptors have been found in the 
vascular smooth muscle [123] and cardiomyo-
cytes [124]. There are data to suggest that low 
levels of 25-hydroxyvitamin-D may be associated 
with accelerated development of cardiovascular 
disease [125]. Supplementation of calcium (Ca) 
and vitamin D for the prevention of osteoporosis 
is frequently found. Recent re-analyses of clinical 
trials observed a higher risk of myocardial infarc-
tion and stroke in subjects taking Ca (+ vitamin D) 
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supplements, although the underlying mecha-
nisms are not clear. The National Osteoporosis 
Foundation and the American Society for Preven-
tive Cardiology adopt the position that calcium 
intake from food and supplements that does not 
exceed the tolerable upper intake level (defined 
by the National Academy of Medicine as 2000 
to 2500 mg/day) should be considered safe from 
a cardiovascular standpoint [126]. Thiele et al. an-
alyzed the associations between Ca and vitamin D 
supplementation as well as serum concentrations 
of Ca and 25-hydroxyvitamin D (25(OH)D) and 
subclinical cardiovascular disease (CVD) pheno-
types, namely intima-media thickness, ankle-bra-
chial index (ABI), intermittent claudication, and 
atrial fibrillation (AF) [127]. Data of 1601 partici-
pants aged 50–81 years of the population-based 
cross-sectional Cooperative Health Research in 
the Region of Augsburg (KORA) F4 study in Ger-
many were analyzed. Regular Ca supplementation 
showed a  significant positive association with 
the presence of AF after multivariable adjustment 
(OR = 3.89; 95% CI: 1.28–11.81) [127]. Higher se-
rum 25(OH)D concentrations were independently 
associated with a lower prevalence of asymptom-
atic peripheral arterial disease as assessed by ABI 
measurements (β = 0.007; p = 0.01). No other sig-
nificant associations between supplementation or 
serum concentrations of Ca or vitamin D and CVD 
phenotypes were identified [127]. The change in 
CIMT in premenopausal women and postmeno-
pausal women after calcium supplementation was 
0.0238 ±0.0348 compared with 0.0615 ±0.134 
mm (p = 0.017), respectively [125].
An observational pilot sub-study of the San 
Valentino epidemiological cardiovascular study 
[128] included 1363 subjects aged 45–60 without 
any conventional risk factors who had non-ste-
nosing atherosclerotic plaques (< 50%) in at least 
one carotid or common femoral bifurcation, al-
located into 6 groups: controls (group 1) – man-
agement was based on education, exercise, diet 
and lifestyle changes, and this same management 
plan was used in all groups; group 2 – Pycnogenol 
50 mg/day (Pycnogenol is the registered trade 
name for a special extract from the outer bark of 
the French maritime pine Pinus pinaster ssp. atlan-
tica and it is highly concentrated in flavonoids, the 
primary constituents being procyanidins, taxifolin, 
ferulic acid, catechin, and caffeic acid) [129]; group 3 
– Pycnogenol 100 mg/day; group 4 – aspirin 
100 mg/day or ticlopidine 250 mg/day if intoler-
ant to aspirin; group 5 – aspirin 100 mg/day and 
Pycnogenol 100 mg/day; group 6 – Pycnogenol 
100 mg/day plus TECA (total triterpenic fraction 
of Centella asiatica) 100 mg/day [128]. There was 
a  6 monthly follow-up up to 30 months. Plaque 
progression was assessed using the ultrasonic ar-
terial score based on the arterial wall morphology 
and the number of plaques that progressed from 
the non-stenotic to the stenotic group. A second-
ary endpoint was to evaluate the changes in ox-
idative stress at baseline and at 30 months. The 
ultrasonic score increased significantly in groups 
1, 2 and 4 but not in groups 3, 5 and 6, suggesting 
a beneficial effect of Pycnogenol 100 mg. The per-
centage of plaques that progressed from class IV 
to class V was 8.4% in group 2; 5.3% in group 3; 
4% in group 5 and 1.1% in group 6 (p < 0.0001) 
compared with 16.6% in group 4 (aspirin) and 
21.3% in the control group, suggesting a  bene-
ficial effect of Pycnogenol [128]. The lowest rate 
of progression was in group 6 (Pycnogenol plus 
TECA). The results justify a large randomized con-
trolled study to demonstrate the efficacy of the 
combined Pycnogenol and TECA prophylactic ther-
apy in subclinical atherosclerosis [128]. 
Zou et al. evaluated the effects of lutein and 
lycopene supplementation on CIMT in subjects 
with subclinical atherosclerosis [130]. A  total of 
144 subjects aged 45–68 years were recruited 
from local communities. All the subjects were 
randomly assigned to receive 20 mg lutein/day 
(n = 48), 20 mg lutein/day + 20 mg lycopene/day 
(n = 48) or placebo (n = 48) for 12 months. Se-
rum lutein concentrations increased significant-
ly from 0.34 to 1.96 µmol/l in the lutein group 
(p < 0.001) and from 0.35 to 1.66 µmol/l in the 
combination group (p < 0.001). Similarly, serum 
lycopene concentrations increased significantly 
from 0.18 to 0.71 µmol/l in the combination group 
at 12 months (p < 0.001), whereas no signifi-
cant change was observed in the placebo group 
[130]. The mean values of CIMT decreased signifi-
cantly by 0.035 mm (p = 0.042) and 0.073 mm 
(p < 0.001) in the lutein and combination groups 
at 12 months, respectively [130]. The change in 
CIMT was inversely associated with the increase 
in serum lutein concentrations (p < 0.05) in both 
the active treatment groups and with the increase 
in serum lycopene concentrations (β = –0.342, 
p = 0.031) in the combination group. Lutein and 
lycopene supplementation significantly increased 
the serum concentrations of lutein and lycopene, 
with a  decrease in CIMT being associated with 
both concentrations. In addition, the combination 
of lutein and lycopene supplementation was more 
effective than lutein alone for protection against 
the development of CIMT in Chinese subjects with 
subclinical atherosclerosis, and further studies are 
needed to confirm whether synergistic effects of 
lutein and lycopene exist [130].
Although epidemiological and experimental 
studies suggest that dietary intake of soy may 
be cardioprotective, use of isoflavone soy protein 
(ISP) supplementation as a  primary preventive 
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Table I. Effects of nutraceuticals on metabolic syndrome components
Nutraceuticals Effects on metabolic syndrome components
Abdominal obesity Blood pressure Glycemic and lipid metabolism
Black rice No effect on plasma lipids [108]
Calcium ↓ Adiponectin [88] ↓ Cholesterol levels [85] 
↓ IFG or diabetes [86]
Chokeberry ↓ Cholesterol [32]
↓ Triglycerides [32]
↓ LDL-C [32]
No effect on glycemic profile [32]
Citrus 
bergamia
↓ Cholesterol [17]
↓ Triglycerides [17]
↓ LDL-C [17]
↑ HDL-C [17]
Curcumin ↓ Body weight [31, 32]
↓ Body fat [31, 32] 
↓ Waistline [31, 32] 
↓ Hip circumference [31]
↓ BMI [31, 32]
↓ Fasting glucose [32]
↓ Total cholesterol [32]
Equol ↓ LDL-C [84]
Garlic ↓ Systolic and diastolic blood 
pressure [42]
GIMM (inulin, 
β-glucan, 
blueberry 
polyphenols)
↓ Ghrelin concentrations [49] ↑ Blood glucose tolerance [49]
No effect on lipid profile [49]
Ginseng ↓ Body weight [57] ↓ Fasting glucose [57]
↓ HbA1c [57]
↑ Insulin [60–64, 66]
↓ Cholesterol [58]
↓ LDL-C [58]
Suppression of HMG-CoA 
reductase [58]
Suppression of cholesterol  
7 α-hydroxylase [58]
Green tea ↓ Body fat, body weight  
[21, 22]
↓ Waist circumference [22]
↓ Blood pressure [21, 38] ↓ Cholesterol [38]
↓ Triglycerides [38]
↓ LDL-C [38]
↑ HDL-C [38]
Mulberry ↓ Adiponectin [52] ↓ Cholesterol [52]
↓ Triglycerides [52]
↓ LDL-C [52]
↑ HDL-C [52]
Omega-3 
fatty acids 
EPA and DHA ↓ adipose tissue 
mass [24]
Beneficial effects of ALA, EPA 
and DHA on systolic  
and diastolic blood pressure  
[44, 45]
↓ Cholesterol [65, 66]
↓ Triglycerides [65, 66]
↓ LDL-C [65, 66, 107]
↑ HDL-C [65, 107, 133]
Phosphorus ↓ Blood pressure [48]
Pomegranate ↓ Blood pressure [35–37]
↓ Systolic blood pressure [112]
No effects on serum glucose, 
cholesterol and triglyceride 
levels [89]
Quercetin Its effects on blood pressure 
have not been conclusive [46] 
↓ Systolic and diastolic blood 
pressure [47]
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therapy remains unexplored. Hodis et al. deter-
mined whether ISP reduces subclinical athero-
sclerosis assessed as cIMT progression [131]. In 
a double-blind, placebo-controlled trial, 350 post-
menopausal women 45 to 92 years of age without 
diabetes and cardiovascular disease were ran-
domized to 2 evenly divided daily doses of 25 g 
soy protein containing 91 mg aglycon isoflavone 
equivalents or placebo for 2.7 years [131]. Over-
all, the mean (95% CI) cIMT progression rate was 
4.77 (3.39–6.16) µm/year in the ISP group and 
5.68 (4.30–7.06) µm/year in the placebo group. 
Although cIMT progression was reduced on av-
erage by 16% in the ISP group relative to the 
placebo group, this treatment effect was not sta-
tistically significant (p = 0.36) [131]. Among the 
subgroup of women who were randomized with-
in 5 years of menopause, ISP participants had on 
average a 68% lower cIMT progression rate than 
placebo participants 2.16 (–1.10 to 5.43) vs. 6.79 
(3.56–10.01) µm/year (p = 0.05). The ISP supple-
mentation had a null effect on women who were 
> 5 years beyond menopause when randomized. 
There were no major adverse events from ISP sup-
plementation [131].
Observational studies have reported inverse 
associations between adherence to the Mediter-
ranean diet (MedDiet) and atherosclerotic dis-
ease. The Primary Prevention of Cardiovascular 
Disease with a  Mediterranean Diet (PREDIMED) 
group tested the effect of two types of MedDiet 
on progression of subclinical carotid atheroscle-
rosis [132]. The group randomized 187 high-car-
diovascular-risk asymptomatic subjects (51% 
women, mean age 67 years) to three treatment 
arms: MedDiet with supplemental virgin olive oil 
(VOO), n = 66; MedDiet with supplemental nuts, 
n = 59; and control diet, n = 62 [132]. After 1 year, 
overall, no significant between-group differences 
in IMT progression were observed. However, a sig-
nificant interaction (p = 0.03) between baseline 
IMT and treatment effect was apparent [132]. 
Among participants with baseline IMT ≥ 0.9 mm, 
1-year IMT changes versus control showed signifi-
cant differences of –0.079 mm (95% CI: –0.145 to 
–0.012) for the MedDiet with VOO and –0.072 mm 
(–0.140 to –0.004) for the MedDiet with nuts. No 
IMT changes occurred in any intervention group 
among participants with lower baseline IMT val-
ues (< 0.9 mm). MedDiets enhanced with VOO 
or nuts were not effective in inducing ultrasono-
graphic regression of carotid atherosclerosis af-
ter 1-year intervention [132]. However, they were 
effective among subjects with elevated baseline 
IMT, suggesting that subclinical atherosclerosis 
may respond to dietary intervention within a rela-
tively short time frame only among subjects with 
a high initial atherosclerotic burden [132].
A randomized study targeted a comparison of 
the effect of 3-year diet counseling or omega-3 
polyunsaturated fatty acid (PUFA) supplementa-
tion (2.4 g/day) on the progression of atheroscle-
rosis in carotid arteries and on finger pulse wave 
propagation [133]. Altogether, 563 elderly men 
Nutraceuticals Effects on metabolic syndrome components
Abdominal obesity Blood pressure Glycemic and lipid metabolism
Resveratrol No effect on BMI, body weight, 
fat mass and abdominal fat 
distribution [28]
Does not reduce plasma levels 
of TC, LDL-C and TG [50]
Soy ↓ LDL-C [84]
Vitamin B3 
(Niacin)
↓ Cholesterol [79–81]
↓ Triglycerides [79–81]
↓ LDL-C [79–81]
↓ Apoprotein B [79–81]
↑ HDL-C [79–81]
Vitamin B12 ↓ LDL-C [120]
Vitamin D No significant change in 
plasma concentrations of 
adiponectin and leptin [29]
↓ Body weight, waist 
circumference and BMI [30]
↓ Systolic blood pressure [30] ↓ HOMA-IR [30]
Zinc ↓ Cholesterol [90]
↓ Triglycerides [90]
↑ HDL-C [90]
↓ Glucose intolerance and 
diabetes [90]
Table I. Cont.
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with long-standing hyperlipidemia were random-
ized to four groups: controls (no dietary counsel-
ing and placebo); dietary counseling (and placebo); 
omega-3 PUFA supplementation (no dietary coun-
seling); dietary counseling and omega-3 PUFA 
supplementation. In the diet only group, the cIMT 
increase (0.929 mm to 0.967 mm) was signifi-
cantly less than in the control group (0.909 mm to 
0.977 mm) (p = 0.018). Significant increases in 
carotid plaques score and plaques area were 
observed in all four groups, but without be-
tween-group differences [133]. Changes in cIMT 
Table II. Effects of nutraceuticals on vascular damage
Nutraceuticals Effects on vascular damage
Prothrombotic and inflammatory states Vascular parameters
Black rice Enhances plasma total antioxidant capacity [108]
↓ sVCAM-1 [108]
↓ sCD40L [108]
No effect on T-SOD [108]
↓ cIMT [108]
Calcium ↓ ROS [88]
↓ NADPH oxidase [88]
↓ MDA [88]
↓ TNF-α [88]
↓ IL-6 [88]
Citrus bergamia ↓ cIMT [17]
Curcumin No effect on parameters, including oxidative 
stress (GSH, LOOH) [32]
Green tea Inhibition of the expression of inducible nitric 
oxide synthase [19]
↑ Levels of glutathione in the blood and 
plasma total antioxidant capacity [58]
Lutein and 
lycopene
↓ cIMT [130]
Magnesium ↓ Inflammation [77]
↓ Oxidative stress [91]
Olive oil No reduction of cIMT [132]
Omega-3 fatty 
acids 
↓ GSH [94, 95]
↑ MDA [94, 95]
↓ MMP-9 [107]
↓ PAPP-A [107]
↓ TIMP-1 [119]
↓ cIMT [133]
No effect on cardiovascular risk [66–71]
Pinus pinaster 
ssp. atlantica
↓ Reduction of plaque [128]
Pomegranate ↓ Oxidative stress [89] ↓ cIMT [112]
Quercetin Antioxidant effects in cardiovascular disease 
[46]
Resveratrol Significant positive effect on inflammatory 
markers [28]
Vitamin B12 No effects on cIMT or pulse wave velocity [118]
↓ cIMT [120–122]
↑ FMD [121]
↓ ABI [127]
Vitamin C ↓ Peroxyl radical formation [96]
↓ NO production by endothelial cells [99]
↑ Red cell glutathione [103]
Vitamin E Blocks the chain reaction of lipid peroxidation 
by scavenging intermediate peroxyl radicals 
[75]
No significant differences in the numbers of 
deaths from cardiovascular causes [76, 77]
Vitamin K2 
(menaquinone)
No effect on the markers for acute phase [105] ↓ cfPWV [100] 
↓ stiffness index β [105]
No effect on endothelial dysfunction [105]
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and in HDL-C were negatively correlated (adjust-
ed p < 0.001). Pulse wave propagation time de-
creased significantly in the control group (206 ms 
to 198 ms; p = 0.002), reflecting reduced arterial 
elasticity. In the group receiving omega-3 PUFA 
only, pulse wave propagation time increased sig-
nificantly when compared with the control group 
(p = 0.013) [133].
Conclusions
Nutraceuticals represent an alternative form 
of medicine compared with the healing tradi-
tions that in the recent past were not part of 
standard medical education. However, more and 
more people are seeking nutraceutical remedies 
for their health care needs. Although most of the 
nutraceutical therapies are relatively harmless, 
there are many unknowns. As this review demon-
strates, there are numerous molecular and cellu-
lar dynamics that may be beneficially impacted 
by many of the components in nutraceuticals. 
There is much yet to be investigated, character-
ized, and learned.
The use of nutraceuticals for the treatment of 
cardiovascular disease is the subject of criticism. 
Nutraceuticals are a  challenge for the education 
of many cardiovascular physicians, with many 
positive effects considered to be placebo effects. 
Some of many existing nutraceutical compounds 
could be used as integrators in a daily diet thanks 
to their easy availability and to their beneficial 
properties, such as in polyphenols, omega-3 fat-
ty acids, macroelements and vitamins used as 
non-pharmacologic treatment. Natural products 
can also be useful in the therapy with metabolic 
syndrome and statin intolerance; especially MetS 
might increase the risk of statin intolerance – via 
liver dysfunction/steatosis [134, 135]. Use of food 
supplements in MetS has a beneficial effect on the 
individual components [136–138]. This results in 
improved blood pressure [139], blood glucose and 
lipids [11, 13, 140, 141]. Vitamin D supplemen-
tation correlates with significant improvements 
in plasma concentrations of adiponectin and 
leptin. Inulin, β-glucan, blueberry anthocyanins, 
and blueberry polyphenols reduce plasma ghrelin 
concentrations and improve blood glucose toler-
ance. The critical importance of phosphorus in cel-
lular structure and function could have profound 
effects on blood pressure regulation through its 
role in plasma membrane structure. Magnesium 
plays a role in regulating vascular tone and endo-
thelial function. Ginseng supplementation low-
ers cholesterol and LDL-C with the suppression 
of β-hydroxy-β-methylglutaryl-CoA reductase. 
White mulberry extract has a  significant impact 
on the changes in the LDL-C subfractions (Table I). 
Adherence to a  low-calorie diet supported with 
supplements promotes weight loss and improves 
the markers of oxidative stress. Bergamot juice 
(neoeriocitrin, neohesperidin, naringin) has an 
effect on metabolic parameters, including plasma 
lipids, atherogenic lipoproteins and subclinical 
atherosclerosis. Vitamin E blocks the chain reac-
tion of lipid peroxidation by scavenging interme-
diate peroxyl radicals, though it has not yet shown 
cardiovascular benefit in prospective randomized 
trials. Quercetin has antioxidant effects since it 
protects against H
2O2-induced lipid peroxidation 
and reduces the cytokine-induced cell-surface 
expression of vascular cell adhesion molecule-1. 
Black rice and its pigment fraction have shown an-
ti-atherogenic activities. There are ongoing stud-
ies (REDUCE-IT and STRENGTH) that will help to 
more firmly establish the role of omega-3 fish oils 
for cardiovascular protection (Table II). It is pos-
sible that food supplements may reduce the risk 
of cardiovascular disease in patients with MetS, 
though many prospective randomized trials will 
have to be performed in order to more reliably es-
tablish this. 
Further studies are needed to evaluate the ef-
ficacy and safety of these natural compounds in 
patients at high cardiovascular risk, because there 
are still conflicting data on some of these and car-
dio-metabolic prevention (for example omega-3 
and resveratrol). Adequate education of clinicians 
and patients regarding the medicinal properties 
of nutraceuticals must be provided regionally and 
globally to ensure both consumer safety and to 
prevent overstating their clinical efficacy.
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